77 research outputs found
Synthetic peptides elicit strong cellular immunity in Visceral Leishmaniasis natural reservoir and contribute to long-lasting polyfunctional T-cells in BALB/c mice.
Reverse vaccinology or immunoinformatics is a computational methodology which integrates data from in silico epitope prediction, associated to other important information as, for example, the predicted subcellular location of the proteins used in the design of the context of vaccine development. This approach has the potential to search for new targets for vaccine development in the predicted proteome of pathogenic organisms. To date, there is no effective vaccine employed in vaccination campaigns against visceral leishmaniasis (VL). For the first time, herein, an in silico, in vitro, and in vivo peptide screening was performed, and immunogenic peptides were selected to constitute VL peptide-based vaccines. Firstly, the screening of in silico potential peptides using dogs naturally infected by L. infantum was conducted and the peptides with the best performance were selected. The mentioned peptides were used to compose Cockt-1 (cocktail 1) and Cockt-2 (cocktail 2) in combination with saponin as the adjuvant. Therefore, tests for immunogenicity, polyfunctional T-cells, and the ability to induce central and effector memory in T-lymphocytes capacity in reducing the parasite load on the spleen for Cockt-1 and Cockt-2 were performed. Among the vaccines under study, Cockt-1 showed the best results, eliciting CD4+ and CD8+ polyfunctional T-cells, with a reduction in spleen parasitism that correlates to the generation of T CD4+ central memory and T CD8+ effector memory cells. In this way, our findings corroborate the use of immunoinformatics as a tool for the development of future vaccines against VL
A vaccine therapy for canine visceral leishmaniasis promoted significant improvement of clinical and immune status with reduction in parasite burden.
Herein, we evaluated the treatment strategy employing a therapeutic heterologous
vaccine composed of antigens of Leishmania braziliensis associated with MPL adjuvant
(LBMPL vaccine) for visceral leishmaniasis (VL) in symptomatic dogs naturally infected
by Leishmania infantum. Sixteen dogs received immunotherapy with MPL adjuvant
(n = 6) or with a vaccine composed of antigens of L. braziliensis associated with MPL
(LBMPL vaccine therapy, n = 10). Dogs were submitted to an immunotherapeutic
scheme consisting of 3 series composed of 10 subcutaneous doses with 10-day
interval between each series. The animals were evaluated before (T0) and 90 days after
treatment (T90) for their biochemical/hematological, immunological, clinical, and parasitological
variables. Our major results showed that the vaccine therapy with LBMPL
was able to restore and normalize main biochemical (urea, AST, ALP, and bilirubin)
and hematological (erythrocytes, hemoglobin, hematocrit, and platelets) parameters.
In addition, in an ex vivo analysis using flow cytometry, dogs treated with LBMPL
vaccine showed increased CD3+ T lymphocytes and their subpopulations (TCD4+ and
TCD8+), reduction of CD21+ B lymphocytes, increased NK cells (CD5?CD16+) and
CD14+ monocytes. Under in vitro conditions, the animals developed a strong antigen-
specific lymphoproliferation mainly by TCD4+ and TCD8+ cells; increasing in both
TCD4+IFN-?+ and TCD8+IFN-?+ as well as reduction of TCD4+IL-4+ and TCD8+IL-4+
lymphocytes with an increased production of TNF-? and reduced levels of IL-10.
Concerning the clinical signs of canine visceral leishmaniasis, the animals showed an important reduction in the number and intensity of the disease signs; increase body
weight as well as reduction of splenomegaly. In addition, the LBMPL immunotherapy
also promoted a reduction in parasite burden assessed by real-time PCR. In the bone
marrow, we observed seven times less parasites in LBMPL animals compared with
MPL group. The skin tissue showed a reduction in parasite burden in LBMPL dogs
127.5 times higher than MPL. As expected, with skin parasite reduction promoted by
immunotherapy, we observed a blocking transmission to sand flies in LBMPL dogs
with only three positive dogs after xenodiagnosis. The results obtained in this study
highlighted the strong potential for the use of this heterologous vaccine therapy as an
important strategy for VL treatment
A vaccine therapy for canine visceral leishmaniasis promoted significant improvement of clinical and immune status with reduction in parasite burden.
Herein, we evaluated the treatment strategy employing a therapeutic heterologous
vaccine composed of antigens of Leishmania braziliensis associated with MPL adjuvant
(LBMPL vaccine) for visceral leishmaniasis (VL) in symptomatic dogs naturally infected
by Leishmania infantum. Sixteen dogs received immunotherapy with MPL adjuvant
(n = 6) or with a vaccine composed of antigens of L. braziliensis associated with MPL
(LBMPL vaccine therapy, n = 10). Dogs were submitted to an immunotherapeutic
scheme consisting of 3 series composed of 10 subcutaneous doses with 10-day
interval between each series. The animals were evaluated before (T0) and 90 days after
treatment (T90) for their biochemical/hematological, immunological, clinical, and parasitological
variables. Our major results showed that the vaccine therapy with LBMPL
was able to restore and normalize main biochemical (urea, AST, ALP, and bilirubin)
and hematological (erythrocytes, hemoglobin, hematocrit, and platelets) parameters.
In addition, in an ex vivo analysis using flow cytometry, dogs treated with LBMPL
vaccine showed increased CD3+ T lymphocytes and their subpopulations (TCD4+ and
TCD8+), reduction of CD21+ B lymphocytes, increased NK cells (CD5?CD16+) and
CD14+ monocytes. Under in vitro conditions, the animals developed a strong antigen-
specific lymphoproliferation mainly by TCD4+ and TCD8+ cells; increasing in both
TCD4+IFN-?+ and TCD8+IFN-?+ as well as reduction of TCD4+IL-4+ and TCD8+IL-4+
lymphocytes with an increased production of TNF-? and reduced levels of IL-10.
Concerning the clinical signs of canine visceral leishmaniasis, the animals showed an important reduction in the number and intensity of the disease signs; increase body
weight as well as reduction of splenomegaly. In addition, the LBMPL immunotherapy
also promoted a reduction in parasite burden assessed by real-time PCR. In the bone
marrow, we observed seven times less parasites in LBMPL animals compared with
MPL group. The skin tissue showed a reduction in parasite burden in LBMPL dogs
127.5 times higher than MPL. As expected, with skin parasite reduction promoted by
immunotherapy, we observed a blocking transmission to sand flies in LBMPL dogs
with only three positive dogs after xenodiagnosis. The results obtained in this study
highlighted the strong potential for the use of this heterologous vaccine therapy as an
important strategy for VL treatment
The Schistosomiasis SpleenOME: Unveiling the Proteomic Landscape of Splenomegaly Using Label-Free Mass Spectrometry
Schistosomiasis is a neglected parasitic disease that affects millions of people worldwide and is caused by helminth parasites from the genus Schistosoma. When caused by S. mansoni, it is associated with the development of a hepatosplenic disease caused by an intense immune response to the important antigenic contribution of adult worms and to the presence of eggs trapped in liver tissue. Although the importance of the spleen for the establishment of immune pathology is widely accepted, it has received little attention in terms of the molecular mechanisms operating in response to the infection. Here, we interrogated the spleen proteome using a label-free shotgun approach for the potential discovery of molecular mechanisms associated to the peak of the acute phase of inflammation and the development of splenomegaly in the murine model. Over fifteen hundred proteins were identified in both infected and control individuals and 325 of those proteins were differentially expressed. Two hundred and forty-two proteins were found upregulated in infected individuals while 83 were downregulated. Functional enrichment analyses for differentially expressed proteins showed that most of them were categorized within pathways of innate and adaptive immunity, DNA replication, vesicle transport and catabolic metabolism. There was an important contribution of granulocyte proteins and antigen processing and presentation pathways were augmented, with the increased expression of MHC class II molecules but the negative regulation of cysteine and serine proteases. Several proteins related to RNA processing were upregulated, including splicing factors. We also found indications of metabolic reprogramming in spleen cells with downregulation of proteins related to mitochondrial metabolism. Ex-vivo imunophenotyping of spleen cells allowed us to attribute the higher abundance of MHC II detected by mass spectrometry to increased number of macrophages (F4/80+/MHC II+ cells) in the infected condition. We believe these findings add novel insights for the understanding of the immune mechanisms associated with the establishment of schistosomiasis and the processes of immune modulation implied in the host-parasite interactions
Immunotherapy and immunochemotherapy in visceral leishmaniasis : promising treatments for this neglected disease.
Leishmaniasis has several clinical forms: self-healing or chronic cutaneous leishmaniasis
or post-kala-azar dermal leishmaniasis; mucosal leishmaniasis; visceral leishmaniasis (VL),
which is fatal if left untreated.The epidemiology and clinical features of VL vary greatly due
to the interaction of multiple factors including parasite strains, vectors, host genetics, and
the environment. Human immunodeficiency virus infection augments the severity of VL
increasing the risk of developing active disease by 100?2320 times. An effective vaccine
for humans is not yet available. Resistance to chemotherapy is a growing problem in many
regions, and the costs associated with drug identification and development, make commercial
production for leishmaniasis, unattractive.The toxicity of currently drugs, their long
treatment course, and limited efficacy are significant concerns. For cutaneous disease,
many studies have shown promising results with immunotherapy/immunochemotherapy,
aimed to modulate and activate the immune response to obtain a therapeutic cure. Nowadays,
the focus of many groups centers on treating canine VL by using vaccines and
immunomodulators with or without chemotherapy. In human disease, the use of cytokines
like interferon-g associated with pentavalent antimonials demonstrated promising results
in patients that did not respond to conventional treatment. In mice, immunomodulation
based on monoclonal antibodies to remove endogenous immunosuppressive cytokines
(interleukin-10) or block their receptors, antigen-pulsed syngeneic dendritic cells, or biological
products like Pam3Cys (TLR ligand) has already been shown as a prospective treatment
of the disease. This review addresses VL treatment, particularly immunotherapy and/or
immunochemotherapy as an alternative to conventional drug treatment in experimental
models, canine VL, and human disease
Prevalence and Factors Associated with Leishmania infantum Infection of Dogs from an Urban Area of Brazil as Identified by Molecular Methods
Visceral leishmaniasis (VL) is a disease caused by the parasite Leishmania infantum, and dogs are the most important domestic reservoirs of the agent. During recent decades, VL has expanded to large Brazilian urban centers. In the present work, we have demonstrated by using molecular techniques that the rate of canine infection as detected by serology has been considerably underestimated. Two groups of seronegative dogs (infected and non-infected according to molecular methods) were further evaluated from data obtained through interviews with owners of the animals. The factors associated with Leishmania infection in dogs were a family income of less than two minimum salaries, the knowledge of the owner regarding the vector, the dog spending most of its time in the backyard and the dog never having had a previous serological examination. Awareness regarding the factors associated with canine infection will improve health services and the understanding of the disease's expansion in urban areas
The TcI and TcII Trypanosoma cruzi experimental infections induce distinct immune responses and cardiac fibrosis in dogs
Pervasive gaps in Amazonian ecological research
Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear un derstanding of how ecological communities respond to environmental change across time and space.3,4
While the increasing availability of global databases on ecological communities has advanced our knowledge
of biodiversity sensitivity to environmental changes,5–7 vast areas of the tropics remain understudied.8–11 In
the American tropics, Amazonia stands out as the world’s most diverse rainforest and the primary source of
Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepre sented in biodiversity databases.13–15 To worsen this situation, human-induced modifications16,17 may elim inate pieces of the Amazon’s biodiversity puzzle before we can use them to understand how ecological com munities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus
crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced
environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple or ganism groups in a machine learning model framework to map the research probability across the Brazilian
Amazonia, while identifying the region’s vulnerability to environmental change. 15%–18% of the most ne glected areas in ecological research are expected to experience severe climate or land use changes by
2050. This means that unless we take immediate action, we will not be able to establish their current status,
much less monitor how it is changing and what is being lostinfo:eu-repo/semantics/publishedVersio
Pervasive gaps in Amazonian ecological research
Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear understanding of how ecological communities respond to environmental change across time and space.3,4 While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes,5,6,7 vast areas of the tropics remain understudied.8,9,10,11 In the American tropics, Amazonia stands out as the world's most diverse rainforest and the primary source of Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepresented in biodiversity databases.13,14,15 To worsen this situation, human-induced modifications16,17 may eliminate pieces of the Amazon's biodiversity puzzle before we can use them to understand how ecological communities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple organism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region's vulnerability to environmental change. 15%–18% of the most neglected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lost
- …